Furthermore , improvements greater than or equal to the minimum clinically important difference were more frequently reported by tofacitinib-treated patients versus placebo for PtGA ( P < @ ) , pain ( P < @ ) , HAQ DI ( P < @ ) , SF-@v@ physical and mental component summary scores ( P < @ ) , and FACIT-F ( P < @ for @ mg twice daily ) .